After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization